Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SACK trial of apixaban for stroke prevention in atrial fibrillation with stage 5 chronic kidney disease
NL-OMON59868Phase 3Recruiting
- Sponsor
- Karolinska University Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Atrial fibrillation (AFib), atrial flutter (AFL) and chronic kidney disease (CKD) comparing Apixaban plus standard of care with Standard of care without anticoagulation (2 arms). Primary endpoint: Ischemic stroke and systemic embolism. Started Apr 2026; status: recruiting.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON59868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59868.